An update from GT Biopharma (GTBP) is now available.
GT Biopharma, Inc. has made a significant change in its executive team by terminating Manu Ohri as Chief Financial Officer and appointing the experienced Alan L. Urban to the role. Urban brings a wealth of knowledge from previous CFO roles across various sectors, including financial technology and cryptocurrency mining, and holds an extensive background in finance and accounting. Under the new employment agreement effective June 3, 2024, Urban will earn a substantial annual salary with potential bonuses, receive stock awards, and be entitled to severance under certain conditions, highlighting the company’s strategic move to strengthen its financial leadership.
See more insights into GTBP stock on TipRanks’ Stock Analysis page.
